[go: up one dir, main page]

WO2006008009A3 - Diagnostics and therapeutics for diseases associated with leucine-rich repeat-containing gpcr 6 (lgr6) - Google Patents

Diagnostics and therapeutics for diseases associated with leucine-rich repeat-containing gpcr 6 (lgr6) Download PDF

Info

Publication number
WO2006008009A3
WO2006008009A3 PCT/EP2005/007458 EP2005007458W WO2006008009A3 WO 2006008009 A3 WO2006008009 A3 WO 2006008009A3 EP 2005007458 W EP2005007458 W EP 2005007458W WO 2006008009 A3 WO2006008009 A3 WO 2006008009A3
Authority
WO
WIPO (PCT)
Prior art keywords
disorders
lgr6
diseases
therapeutics
diagnostics
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2005/007458
Other languages
French (fr)
Other versions
WO2006008009A2 (en
Inventor
Stefan Golz
Ulf Brueggemeier
Andreas Geerts
Holger Summer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer AG
Original Assignee
Bayer Healthcare AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Healthcare AG filed Critical Bayer Healthcare AG
Publication of WO2006008009A2 publication Critical patent/WO2006008009A2/en
Publication of WO2006008009A3 publication Critical patent/WO2006008009A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

The invention provides a human LGR6 which is associated with the cardiovascular disorders, endocrine system and hormone disorders, metabolic diseases, hematological disorders, respiratory diseases, inflammatory diseases, neurological disorders, reproduction disorders, cancer disorders and urological disorders. The invention also provides assays for the identification of compounds useful in the treatment or prevention of cardiovascular disorders, endocrine system and hormone disorders, metabolic diseases, hematological disorders, respiratory diseases, inflammatory diseases, neurological disorders, reproduction disorders, cancer disorders and urological disorders. The invention also features compounds which bind to and/or activate or inhibit the activity of LGR6 as well as pharmaceutical compositions comprising such compounds.
PCT/EP2005/007458 2004-07-23 2005-07-09 Diagnostics and therapeutics for diseases associated with leucine-rich repeat-containing gpcr 6 (lgr6) Ceased WO2006008009A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP04017452 2004-07-23
EP04017452.6 2004-07-23

Publications (2)

Publication Number Publication Date
WO2006008009A2 WO2006008009A2 (en) 2006-01-26
WO2006008009A3 true WO2006008009A3 (en) 2006-06-08

Family

ID=35432059

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2005/007458 Ceased WO2006008009A2 (en) 2004-07-23 2005-07-09 Diagnostics and therapeutics for diseases associated with leucine-rich repeat-containing gpcr 6 (lgr6)

Country Status (1)

Country Link
WO (1) WO2006008009A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10926001B2 (en) 2014-12-02 2021-02-23 Polarityte, Inc. Methods related to minimally polarized functional units

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003025148A2 (en) * 2001-09-19 2003-03-27 Nuvelo, Inc. Novel nucleic acids and polypeptides
WO2004040000A2 (en) * 2002-09-09 2004-05-13 Nura, Inc G protein coupled receptors and uses thereof
WO2004058818A2 (en) * 2002-12-26 2004-07-15 Applied Research Systems Ars Holding N.V. Spliced variants of lgr6

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003025148A2 (en) * 2001-09-19 2003-03-27 Nuvelo, Inc. Novel nucleic acids and polypeptides
WO2004040000A2 (en) * 2002-09-09 2004-05-13 Nura, Inc G protein coupled receptors and uses thereof
WO2004058818A2 (en) * 2002-12-26 2004-07-15 Applied Research Systems Ars Holding N.V. Spliced variants of lgr6

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
SHEAU YU HSU ET AL: "THE THREE SUBFAMILIES OF LEUCINE-RICH REPEAT-CONTAINING G PROTEIN-COUPLED RECEPTORS (LGR): IDENTIFICATION OF LGR6 AND LGR7 AND THE SIGNALING MECHANISM FOR LGR7", MOLECULAR ENDOCRINOLOGY, BALTIMORE, MD, US, vol. 14, 2000, pages 1257 - 1271, XP001052691, ISSN: 0888-8809 *
VAN SCHOORE GREGORY ET AL: "Expression pattern of the orphan receptor LGR4/GPR48 gene in the mouse", HISTOCHEMISTRY AND CELL BIOLOGY, vol. 124, no. 1, July 2005 (2005-07-01), pages 35 - 50, XP002358656, ISSN: 0948-6143 *

Also Published As

Publication number Publication date
WO2006008009A2 (en) 2006-01-26

Similar Documents

Publication Publication Date Title
WO2005093092A3 (en) Diagnostics and therapeutics for diseases associated with g-protein coupled receptor 44 (gpr44)
WO2005050225A3 (en) Diagnostics and therapeutics for diseases associated with g protein-coupled receptor 84 (gpr84)
WO2004099782A3 (en) Diagnostics and therapeutics for diseases associated with g-protein-coupled receptor gpr39 (gpr39)
WO2005095973A3 (en) Diagnostics and therapeutics for diseases associated with g-protein coupled receptor 54 (gpr54)
WO2005040825A3 (en) Diagnostics and therapeutics for diseases associated with g protein-coupled receptor 20 (gpr20)
WO2004082568A3 (en) Diagnostics and therapeutics for diseases associated with complement component 5a receptor (c5ar)
WO2005040211A3 (en) Diagnostics and therapeutics for diseases associated with g protein-coupled receptor 1 (gpr1)
WO2006008009A3 (en) Diagnostics and therapeutics for diseases associated with leucine-rich repeat-containing gpcr 6 (lgr6)
WO2004099783A3 (en) Diagnostics and therapeutics for diseases associated with g-protein-coupled receptor ltb4 (ltb4)
WO2005040829A3 (en) Diagnostics and therapeutics for diseases associated with g protein-coupled receptor 17 (gpr17)
WO2005059546A3 (en) Diagnostics and therapeutics for diseases associated with g protein-coupled receptor 35 (gpr35)
WO2005059504A3 (en) Diagnostics and therapeutics for diseases associated with g protein-coupled receptor gpr34 (gpr34)
WO2004086034A3 (en) Diagnostics and therapeutics for diseases associated with g-protein-coupled receptor adenosine a3(adora3)
WO2005040822A3 (en) Diagnostics and therapeutics for diseases associated with g protein-coupled receptor 25 (gpr25)
WO2004099781A3 (en) Diagnostics and therapeutics for diseases associated with g-protein-coupled receptor rdc1 (rdc1)
WO2005074969A3 (en) Diagnostics and therapeutics for diseases associated with human nuclear receptor nr4a1 (nr4a1)
WO2005095984A3 (en) Diagnostics and therapeutics for diseases associated with g protein-coupled alpha 2a-adrenoceptor (adra2a)
WO2004106935A3 (en) Diagnostics and therapeutics for diseases associated with g protein-coupled receptor 103 (gpr103)
WO2004082571A3 (en) Diagnostics and therapeutics for diseases associated with g protein-coupled receptor 86 (gpr86)
WO2004099248A3 (en) Diagnostics and therapeutics for diseases associated with g-protein-coupled receptor agtr2 (agtr2)
WO2005093091A3 (en) Diagnostics and therapeutics for diseases associated with g-protein coupled receptor 26 (gpr26)
WO2005040824A3 (en) Diagnostics and therapeutics for diseases associated with g protein-coupled receptor 24 (gpr24)
WO2004106934A3 (en) Diagnostics and therapeutics for diseases associated with 5-hydroxytryptamine (serotonin) receptor 7 (5-ht7)
WO2005040790A3 (en) Diagnostics and therapeutics for diseases associated with g protein-coupled receptor 75 (gpr75)
WO2005003779A3 (en) Diagnostics and therapeutics for diseases associated with sensory neuron-specific g protein-coupled receptor 3 (snsr3)

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase